Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 407,468 | 981,126 | 1,680,372 | 1,074,271 | 692,884 |
| Depreciation Amortization | 5,369,571 | 2,452,014 | 1,639,143 | 2,071,919 | 1,638,262 |
| Accounts receivable | -320,399 | -120,438 | -5,823 | -347,030 | 102,688 |
| Accounts payable and accrued liabilities | -275,374 | -147,717 | 61,758 | 395,780 | 148,653 |
| Other Working Capital | 870,982 | 683,514 | 120,636 | 513,035 | -2,034,471 |
| Other Operating Activity | 109,470 | -892,188 | -95,400 | -1,277,299 | -336,440 |
| Operating Cash Flow | $6,161,718 | $2,956,311 | $3,400,686 | $2,430,676 | $211,575 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,053,437 | -242,640 | -576,360 | -545,510 | -400,309 |
| Net Acquisitions | 4,201,235 | -25,861,990 | 510,768 | -4,880,072 | -58,532 |
| Purchase Of Investment | -69,469 | -153,891 | -151,947 | -763,586 | -332,141 |
| Sale Of Investment | 454,498 | 585,315 | 366,687 | 699,992 | 468,568 |
| Purchase Sale Intangibles | -833,778 | -507,933 | -551,313 | -468,413 | -299,622 |
| Other Investing Activity | -845,332 | 151,926 | -989,226 | -608,751 | -268,613 |
| Investing Cash Flow | $2,687,495 | $-25,521,280 | $-840,078 | $-6,097,926 | $-591,026 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,564,948 | 25,163,330 | 3,541,077 | 2,420,102 | 664,000 |
| Debt Repayment | -6,449,725 | N/A | -1,260,000 | -1,783,396 | -249,100 |
| Common Stock Repurchased | -34,380 | -10,548 | -168,804 | -214,988 | -185,472 |
| Dividend Paid | -2,599,754 | -1,286,568 | -1,277,037 | -1,317,698 | -1,174,765 |
| Other Financing Activity | -4,729,049 | 2,649,916 | -3,771,270 | 3,592,013 | -90,828 |
| Financing Cash Flow | $-9,247,960 | $26,516,130 | $-2,936,034 | $2,696,033 | $-1,036,164 |
| Exchange Rate Effect | -200,247 | -281,421 | -41,085 | -53,410 | -276,058 |
| Beginning Cash Position | 6,465,042 | 2,654,757 | 2,875,095 | 4,198,262 | 5,438,517 |
| End Cash Position | 5,866,049 | 6,324,498 | 2,654,757 | 2,970,931 | 3,746,836 |
| Net Cash Flow | $-598,993 | $3,669,741 | $-220,338 | $-1,227,330 | $-1,691,681 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,161,718 | 2,956,311 | 3,400,686 | 2,430,676 | 211,575 |
| Capital Expenditure | -1,169,154 | -699,093 | -603,045 | -573,438 | -404,691 |
| Free Cash Flow | 4,992,564 | 2,257,218 | 2,797,641 | 1,857,238 | -193,116 |